Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity
Biomea Fusion Inc. has launched a Phase I trial for its oral GLP-1 agonist, BMF-650, aimed at obesity treatment. Preclinical data presented at ObesityWeek® 2025 showed significant weight loss and improved glycemic control in obese monkeys. The trial is currently enrolling healthy obese patients, with results expected in early 2026. Additionally, Biomea plans to evaluate its menin inhibitor, icovamenib, in type 2 diabetes patients by late 2025, with first dosing anticipated in early 2026.
Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek® 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568770-en) on November 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
